Purpose: The data on the association between hormone replacement therapy and the increased risk of venous thromboembolism (VTE) in postmenopausal women are conflicting. The observed differences between oral estrogen and oral estrogen-progestogen combination formulations may be the result of bias from depletion of susceptibles.
Methods: We used United Kingdom's Clinical Practice Research Datalink to identify the cohort of all women aged 50 to 79 during 1987-2008, with all incident cases of VTE occurring during the study period identified. Using a nested case-control approach, the rate ratios (RRs) of VTE with current use of oral estrogen and oral estrogen-progestogen combinations were estimated as a function of duration of use using conditional logistic regression with cubic splines.
Results: The cohort of 955 582 postmenopausal women included 23 505 cases of VTE matched to 231 562 controls. The risk of VTE was increased with current use of oral estrogen (RR 1.49; 95% confidence interval: 1.37 to 1.63) and oral estrogen-progestogen (RR 1.54; 95% confidence interval: 1.44 to 1.65), relative to non-use. When assessed by duration of use, the risks with oral formulations were particularly elevated during the first year of use and were reduced subsequently.
Conclusion: The phenomenon of depletion of susceptibles should be considered in cohort studies evaluating acute side effects of medications. This can be achieved by estimating the risk as a function not only of current use but also of duration of use. Copyright © 2017 John Wiley & Sons, Ltd.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.4197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Length of hospital stay in adolescents receiving high-dose oral contraceptive pills with and without conjugated equine estrogen for the treatment of acute abnormal uterine bleeding.
J Pediatr Adolesc Gynecol
January 2025
Division of Adolescent and Young Adult Medicine, Children's Hospital Los Angeles, Keck School of Medicine of University of Southern California, 3250 Wilshire Blvd, Suite 300, Los Angeles, CA 90010.
Study Objective: Compare the length of hospital stay of adolescents admitted for severe anemia (hemoglobin ≤ 8 g/dL) due to acute abnormal uterine bleeding (AUB) treated with high-dose combined oral contraceptive pills (HD-OCPs) versus those treated with HD-OCPs and intravenous conjugated equine estrogen, also referred to as dual therapy.
Design, Setting, And Participants: This is a single institution retrospective cohort study of adolescents hospitalized for the management of acute AUB and severe anemia between July 1, 2004, to January 1, 2020. Subjects were excluded if they were pregnant, had a malignancy, thrombocytopenia, treated with other hormonal therapies, or if bleeding stopped prior to admission.
Sex-specific effects of prenatal bisphenol A exposure on transcriptome-interactome profiles of autism candidate genes in neural stem cells from offspring hippocampus.
Sci Rep
January 2025
Chulalongkorn Autism Research and Innovation Center of Excellence (Chula ACE), Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, 154 Soi Chula 12, Rama 1 Road, Wangmai, Pathumwan, Bangkok, 10330, Thailand.
Bisphenol A (BPA), an endocrine-disrupting chemical, is increasingly linked to the pathogenesis of autism spectrum disorder (ASD). This study investigates the effects of prenatal BPA exposure on neural stem cells (NSCs) from the hippocampi of rat offspring, a brain region critical for neurodevelopment and implicated in ASD. Pregnant rats were administered with BPA or vehicle control once daily via oral gavage from gestational day 1 until parturition.
View Article and Find Full Text PDFPrenatal bisphenol A and/or diethylhexyl phthalate exposure followed by adult estradiol treatment affects behavior and brain monoamines in female rat offspring.
Front Endocrinol (Lausanne)
January 2025
Biomedical and Translational Sciences Institute, Neuroscience Division, Athens, GA, United States.
Significance: Women are at increased risk for mood disorders, which may be partly attributed to exposure to endocrine-disrupting chemicals (EDCs) during sensitive periods such as pregnancy. Exposure during these times can impact brain development in the offspring, potentially leading to mood disorders in later life. Additionally, fluctuating levels of endogenous estrogens, as seen during pregnancy, or the use of oral contraceptives, can further elevate this risk.
View Article and Find Full Text PDFFeasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial.
PLoS One
January 2025
McMaster Immunology Research Centre and Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: A dysbiotic vaginal microbiome (VMB) is associated with clinical conditions such as bacterial vaginosis (BV) and an increased risk of human immunodeficiency virus (HIV-1) infection. Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.
Methods: ACB women aged 18-49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.
Onabotulinum Toxin A-Led Urinary Tract Infections-Should we Safeguard? A Randomized Controlled Trial.
Int Urogynecol J
January 2025
Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA.
Introduction And Hypothesis: The objective of our study was to evaluate the need for antibiotic prophylaxis for urinary tract infection (UTI) prevention before Onabotulinum toxin A injection for overactive bladder (OAB). We hypothesize that the lack of antibiotic prophylaxis might not be inferior to administering prophylaxis.
Methods: This was a multi-centered, nonblinded, randomized controlled trial conducted between August 2022 and September 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!